Category - Markets

Markets

BTIG starts Matinas BioPharma at buy; PT $5

BTIG launched coverage of Matinas BioPharma Holdings (NYSE AMER:MTNB) with a “buy” rating and $5 price target. The stock closed at 94 cents on May 16.

May 17, 2019

Markets

Alliance Global starts T2 Biosystems at buy; PT $5.00

Alliance Global Partners launched coverage of T2 Biosystems (NASDAQ:TTOO) with a “buy” rating and price target of $5.00. The stock closed at $2.62 on May 15.

May 16, 2019

Markets

BTIG cuts electroCore to neutral

BTIG downgraded electroCore (NASDAQ:ECOR) to a “neutral” rating following the company’s release of its first quarter 2019 results. The stock closed at $5.33 on May 14.

May 15, 2019

Markets

BTIG ups TransEnterix to buy; PT $3

BTIG upgraded TransEnterix (NASDAQ:TRXC) to “buy” from “neutral” with a price target of $3, saying it sees more upside potential than downside risk at current share prices.

May 14, 2019

Markets

Roth starts Seelos Therapeutics at buy; PT $8

Roth Capital partners launched coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $8 price target. The stock closed at $2.71 on May 13.

May 14, 2019

Markets

BTIG starts MannKind at buy; PT $3

BTIG initiated coverage of MannKind (NASDAQ:MNKD) with a “buy” rating and price target of $3. The stock closed at $1.23 on May 13.

May 14, 2019

Markets

Alliance Global starts Canopy Growth at buy; PT $75 (Canadian)

Alliance Global Partners launched coverage of Canopy Growth (TSX:WEED; NYSE:CGC) with a “buy” rating and $75 price target. The stock closed at $63.78 on May 10.

May 13, 2019

Markets

SVB Leerink starts Turning Point Therapeutics at OP; PT $42

SVB Leerink launched coverage of Turning Point Therapeutics (NASDAQ:TPTX) with an “outperform” rating and $42 price target. The stock closed at $32.12 on May 10.

May 13, 2019

Markets

SVB Leerink starts Hookipa Pharma at OP; PT $20

SVB Leerink initiated coverage of Hookipa Pharma (NASDAQ:HOOK) with an “outperform” rating and $20 price target. The stock closed at $13.85 on May 10.

May 13, 2019

Markets

Canaccord ups ShockWave Medical PT to $50 from $39

Canaccord Genuity raised its price target for ShockWave Medical (NASDAQ:SWAV) to $50 from $39 after the company’s first quarter results beat consensus estimates.

May 9, 2019

Category - Markets

BTIG starts Matinas BioPharma at buy; PT $5

Alliance Global starts T2 Biosystems at buy; PT $5.00

BTIG cuts electroCore to neutral

BTIG ups TransEnterix to buy; PT $3

Roth starts Seelos Therapeutics at buy; PT $8

BTIG starts MannKind at buy; PT $3

Alliance Global starts Canopy Growth at buy; PT $75 (Canadian)

SVB Leerink starts Turning Point Therapeutics at OP; PT $42

SVB Leerink starts Hookipa Pharma at OP; PT $20

Canaccord ups ShockWave Medical PT to $50 from $39

General

More